These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Thompson KM; Kalkowska DA; Badizadegan K Front Public Health; 2023; 11():1098419. PubMed ID: 37033033 [TBL] [Abstract][Full Text] [Related]
3. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263 [TBL] [Abstract][Full Text] [Related]
4. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237 [TBL] [Abstract][Full Text] [Related]
5. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934 [TBL] [Abstract][Full Text] [Related]
6. The risk of type 2 oral polio vaccine use in post-cessation outbreak response. McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220 [TBL] [Abstract][Full Text] [Related]
7. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Kalkowska DA; Thompson KM Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466 [TBL] [Abstract][Full Text] [Related]
8. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021. Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073 [TBL] [Abstract][Full Text] [Related]
9. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925 [TBL] [Abstract][Full Text] [Related]
10. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659 [TBL] [Abstract][Full Text] [Related]
11. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071 [TBL] [Abstract][Full Text] [Related]
12. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever. Orenstein WA; Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328 [TBL] [Abstract][Full Text] [Related]
13. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Duintjer Tebbens RJ; Thompson KM Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767 [TBL] [Abstract][Full Text] [Related]
14. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272 [TBL] [Abstract][Full Text] [Related]
15. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame. Badizadegan K; Kalkowska DA; Thompson KM Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803 [TBL] [Abstract][Full Text] [Related]